Intellia Therapeutics Inc (NTLA) Director Jean Francois Formela Sells 39,245 Shares
Intellia Therapeutics Inc (NASDAQ:NTLA) Director Jean Francois Formela sold 39,245 shares of the business’s stock in a transaction on Tuesday, March 20th. The shares were sold at an average price of $23.87, for a total transaction of $936,778.15. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Intellia Therapeutics Inc (NASDAQ NTLA) traded up $1.17 during trading hours on Friday, reaching $24.22. 618,761 shares of the company were exchanged, compared to its average volume of 1,192,748. Intellia Therapeutics Inc has a 52 week low of $11.15 and a 52 week high of $35.99. The stock has a market capitalization of $994.41, a price-to-earnings ratio of -12.87 and a beta of 2.42.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Wednesday, March 14th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.16). Intellia Therapeutics had a negative return on equity of 31.27% and a negative net margin of 258.62%. The business had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $8.84 million. During the same period last year, the company earned ($0.31) earnings per share. The firm’s revenue was up 19.6% compared to the same quarter last year. sell-side analysts predict that Intellia Therapeutics Inc will post -2.27 EPS for the current fiscal year.
NTLA has been the subject of a number of recent analyst reports. Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a research note on Tuesday, December 12th. BidaskClub raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. TheStreet raised shares of Intellia Therapeutics from a “d” rating to a “c-” rating in a research note on Monday. JMP Securities initiated coverage on shares of Intellia Therapeutics in a research note on Thursday, March 8th. They set an “outperform” rating for the company. Finally, Barclays boosted their target price on shares of Intellia Therapeutics from $33.00 to $46.00 and gave the company an “overweight” rating in a research note on Wednesday, March 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $34.83.
WARNING: “Intellia Therapeutics Inc (NTLA) Director Jean Francois Formela Sells 39,245 Shares” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/intellia-therapeutics-inc-ntla-director-jean-francois-formela-sells-39245-shares/1960832.html.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.